Medication info
Zadis Duo Sustained Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Zadis Duo Sustained Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Yellow oblong sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501247 · Approved 2025.05.21 · Insurance code 657808420

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To preserve its extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. ⦁ When this drug is taken by patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. As dosage adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if the drug is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Blood sugar control problems
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes, in conjunction with dietary and exercise regimens, by combining empagliflozin and metformin. It is particularly suitable for patients whose blood sugar is not adequately controlled, and those with cardiovascular disease should refer to the related precautions. Thus, this medication effectively aids in managing blood sugar in type 2 diabetes patients and contributes to improving their health.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To preserve its extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. ⦁ When this drug is taken by patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. As dosage adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if the drug is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is an antidiabetic agent that helps control blood sugar levels. However, there are several precautions to be taken when using this drug. First, due to the presence of metformin, there is a rare risk of lactic acidosis, a serious side effect that should be reported to a doctor immediately if suspected. Additionally, co-administration with insulin or sulfonylureas may result in hypoglycemia, so caution is required. Patients with impaired kidney function, acute infections, dehydration, and certain diseases such as heart failure should not take this medication. It should be discontinued before tests or surgeries involving iodinated contrast agents and resumed only after kidney function has normalized. This medication may increase urine output, causing fluid loss, thus special caution is needed for patients at risk of dehydration or the elderly. During treatment, urinary tract infections or genital infections may occur, and if symptoms appear, immediate treatment is required. Vitamin B12 levels may decrease, so regular monitoring is advisable. Alcohol consumption can increase the risk of lactic acidosis, thus excessive drinking should be avoided during treatment. It is recommended that pregnant or breastfeeding women do not use this medication. Additionally, this medication should be swallowed whole without chewing or crushing, and it is normal for the tablet shell to appear in the stool. While taking this medication, blood sugar levels and kidney function should be monitored regularly, and any abnormal symptoms should be discussed with healthcare providers.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • vitamin B12 reduction and deficiency
  • ketoacidosis
  • lactic acidosis
Show 146 more
  • decreased fluid volume
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • increased urination
  • urinary difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated blood creatinine
  • decreased glomerular filtration rate
  • vomiting
  • diarrhea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • gastrointestinal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorder
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • orthostatic dizziness
  • sensory disturbance
  • drowsiness
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • muscle weakness
  • chest discomfort
  • chest pain
  • fever
  • chills
  • strange sensation
  • edema
  • pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urine retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • sputum retention
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • ligament syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. Furthermore, it should be stored at room temperature between 1°C and 30°C, away from extreme heat or cold.

Appearance and packaging

Appearance

Yellow oblong sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.